Suppr超能文献

动物保健制剂中L-648,548及其主要降解产物的稳定性研究和高效液相色谱法

Stability studies and high-performance liquid chromatographic procedures for L-648,548 and its major degradates in an animal health formulation.

作者信息

Faulkner A J, Wang Q, DeMontigny P, Murphy J S

机构信息

Merck Research Laboratories, West Point, PA 19486-0004, USA.

出版信息

J Pharm Biomed Anal. 1997 Jan;15(4):523-36. doi: 10.1016/s0731-7085(96)01877-8.

Abstract

L-648,548 is a new avermectin which was evaluated for the development of an animal health formulation. A stability-indicating method for the essay of 5% (w/v) L-648,548 in an animal health formulation has been developed using reversed-phase high-performance liquid chromatography (HPLC) with UV detection (245 nm). The procedure to determine L-648,548 is linear and accurate over the range 80-120% of the target concentration with a limit of quantitation of 0.2%. Validation data are presented. Also two related degradates of this compound were observed during the stability studies of the L-648,548 formulation. These degradates were determined to be the 2-epimer formed in the presence of base and the 8a-oxo degradate formed by oxidation. Identification of these compounds following direct chemical synthesis was based on mass, UV and NMR spectroscopy. The mechanistic pathways for the formation of these degradates are discussed. The 8a-oxo degradate has a modified chromophore, thus requiring a second HPLC method with detection at 280 nm that was also validated.

摘要

L-648,548是一种新型阿维菌素,正在对其进行评估以开发动物保健制剂。已开发出一种稳定性指示方法,用于采用带紫外检测(245 nm)的反相高效液相色谱法(HPLC)测定动物保健制剂中5%(w/v)的L-648,548。测定L-648,548的方法在目标浓度的80 - 120%范围内呈线性且准确,定量限为0.2%。给出了验证数据。在L-648,548制剂的稳定性研究过程中还观察到了该化合物的两种相关降解产物。这些降解产物被确定为在碱存在下形成的2-差向异构体以及由氧化形成的8a-氧代降解产物。通过直接化学合成后对这些化合物的鉴定基于质谱、紫外光谱和核磁共振光谱。讨论了这些降解产物的形成机理途径。8a-氧代降解产物具有修饰的发色团,因此需要第二种在280 nm处检测的HPLC方法,该方法也经过了验证。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验